Neuroscience
News about this controversial issue (See the list at the bottom of this posting for earlier BrainBlog posts.)
From the company's press release:~
Previous BrainBlog postings on this topic:
20 May 2005
19 May 2005
07 April 2005
04 February 2005
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Fda Approves Invega (paliperidone)
An FDA Press Release: FOR IMMEDIATE RELEASE P06-208 December 20, 2006 Media Inquiries: Press Office, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Approves New Drug for Schizophrenia The Food and Drug Administration (FDA) today approved Invega (paliperidone)...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Business World: Cyberonics And Neurostimulators (vagal Nerve Stimulator [vns])
Tomorrow's New York Times includes an article about the current state of FDA consideration of the Cyberonics VNS device for the treatment of depression. The article is notable for the number of interviews across the spectrum of opinion on this pending...
- Business World: Cyberonics And Neurostimulators (vagal Nerve Stimulator [vns])
From Reuters: Cyberonics falls as Senate probes FDA turnaround Thu May 19, 2005 10:07 AM ET CHICAGO (Reuters) - Shares of Cyberonics Inc. fell almost 13 percent on Thursday after the Senate Finance Committee began examining the FDA's handling of...
- Business World: Cyberonics And Neurostimulators
The Houston Press, which is an alternative news weekly in Houston, has a feature article this week about Cyberonics and its epilepsy device and its exploration of applications in mood disorders: Exposed Nerve Cyberonics has implanted its pacemaker in...
Neuroscience
Business World: Cyberonics, Neurostimulator (Vagus Nerve Stimulator [VNS]), and Depression
News about this controversial issue (See the list at the bottom of this posting for earlier BrainBlog posts.)
From the company's press release:
FDA APPROVES CYBERONICS’ VNS THERAPY™ SYSTEM FOR TREATMENT-RESISTANT DEPRESSION (TRD){ ... Read the Full Press Release ... ]
First FDA-Approved Treatment Specifically for TRD First Implantable Device-Based Treatment for Depression
Conference Call Scheduled for Monday, July 18 at 8:00 AM EDT Investor/Analyst Day at Cyberonics Scheduled for July 25-26
HOUSTON, Texas, July 15, 2005 -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that the United States Food and Drug Administration (FDA) approved the Vagus Nerve Stimulation (VNS) Therapy System “for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.” VNS Therapy is delivered from a small pacemaker-like generator implanted in the chest that sends preprogrammed, intermittent, mild electrical pulses through the vagus nerve in the neck to the brain. The VNS Therapy System is the first FDA-approved implantable device-based treatment for depression and the first treatment developed, studied, approved and labeled specifically for patients with treatment-resistant depression (TRD). The VNS Therapy System was approved as a treatment for medically refractory epilepsy in Europe in 1994 and in the United States and Canada in 1997 and as a treatment for TRD in Europe and Canada in 2001.
Previous BrainBlog postings on this topic:
20 May 2005
19 May 2005
07 April 2005
04 February 2005
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Fda Approves Invega (paliperidone)
An FDA Press Release: FOR IMMEDIATE RELEASE P06-208 December 20, 2006 Media Inquiries: Press Office, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Approves New Drug for Schizophrenia The Food and Drug Administration (FDA) today approved Invega (paliperidone)...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Business World: Cyberonics And Neurostimulators (vagal Nerve Stimulator [vns])
Tomorrow's New York Times includes an article about the current state of FDA consideration of the Cyberonics VNS device for the treatment of depression. The article is notable for the number of interviews across the spectrum of opinion on this pending...
- Business World: Cyberonics And Neurostimulators (vagal Nerve Stimulator [vns])
From Reuters: Cyberonics falls as Senate probes FDA turnaround Thu May 19, 2005 10:07 AM ET CHICAGO (Reuters) - Shares of Cyberonics Inc. fell almost 13 percent on Thursday after the Senate Finance Committee began examining the FDA's handling of...
- Business World: Cyberonics And Neurostimulators
The Houston Press, which is an alternative news weekly in Houston, has a feature article this week about Cyberonics and its epilepsy device and its exploration of applications in mood disorders: Exposed Nerve Cyberonics has implanted its pacemaker in...